(IDXX) IDEXX Laboratories - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US45168D1046
Stock: Veterinary Analyzers, Water Tests, Lab Services, Software Platform
Total Rating 79
Risk 87
Buy Signal -0.57
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 33.9% |
| Relative Tail Risk | -19.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.89 |
| Alpha | 22.07 |
| Character TTM | |
|---|---|
| Beta | 0.988 |
| Beta Downside | 0.566 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.41% |
| CAGR/Max DD | 0.27 |
Description: IDXX IDEXX Laboratories January 29, 2026
IDEXX Laboratories (NASDAQ: IDXX) develops, manufactures, and distributes diagnostic and software solutions for companion-animal veterinary practices, water-quality testing, and livestock-poultry-dairy markets. The firm operates through three segments – Companion Animal Group, Water Quality Products, and Livestock, Poultry & Dairy – offering in-clinic analyzers, rapid SNAP test kits, cloud-based VetConnect PLUS, and a suite of reference-lab services.
Key recent metrics (Q4 2025 / FY 2025): revenue $4.02 billion, up 9 % YoY, driven by a 12 % increase in Companion Animal consumables and a 7 % rise in Water Quality product sales; operating margin expanded to 22.4 % as R&D efficiency improved; cash flow from operations reached $1.1 billion, supporting a $1.2 billion share-repurchase program. Sector drivers include a 5-year CAGR of ~6 % in U.S. pet-care spending, tightening EPA regulations that boost demand for rapid water-testing kits, and rising global protein demand that underpins livestock-diagnostic adoption.
For a deeper, data-driven comparison of IDXX’s valuation and risk profile relative to its peers, the ValueRay platform provides transparent analytics you can explore on your own.
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income: 1.06b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.32 > 0.02 and ΔFCF/TA 7.32 > 1.0 |
| NWC/Revenue: 6.16% < 20% (prev 8.52%; Δ -2.36% < -1%) |
| CFO/TA 0.35 > 3% & CFO 1.18b > Net Income 1.06b |
| Net Debt (667.8m) to EBITDA (1.47b): 0.45 < 3 |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (80.7m) vs 12m ago -2.87% < -2% |
| Gross Margin: 61.80% > 18% (prev 0.61%; Δ 6119 % > 0.5%) |
| Asset Turnover: 129.5% > 50% (prev 118.3%; Δ 11.21% > 0%) |
| Interest Coverage Ratio: 27.36 > 6 (EBITDA TTM 1.47b / Interest Expense TTM 38.3m) |
Altman Z'' 9.58
| A: 0.08 (Total Current Assets 1.41b - Total Current Liabilities 1.15b) / Total Assets 3.35b |
| B: 1.83 (Retained Earnings 6.14b / Total Assets 3.35b) |
| C: 0.32 (EBIT TTM 1.05b / Avg Total Assets 3.32b) |
| D: 0.92 (Book Value of Equity 1.61b / Total Liabilities 1.75b) |
| Altman-Z'' Score: 9.58 = AAA |
Beneish M -2.89
| DSRI: 1.06 (Receivables 552.4m/473.6m, Revenue 4.30b/3.90b) |
| GMI: 0.99 (GM 61.80% / 61.08%) |
| AQI: 1.10 (AQ_t 0.36 / AQ_t-1 0.32) |
| SGI: 1.10 (Revenue 4.30b / 3.90b) |
| TATA: -0.04 (NI 1.06b - CFO 1.18b) / TA 3.35b) |
| Beneish M-Score: -2.89 (Cap -4..+1) = A |
What is the price of IDXX shares?
As of February 07, 2026, the stock is trading at USD 644.61 with a total of 562,640 shares traded.
Over the past week, the price has changed by -3.86%, over one month by -8.80%, over three months by -9.69% and over the past year by +39.96%.
Over the past week, the price has changed by -3.86%, over one month by -8.80%, over three months by -9.69% and over the past year by +39.96%.
Is IDXX a buy, sell or hold?
IDEXX Laboratories has received a consensus analysts rating of 3.62.
Therefor, it is recommend to hold IDXX.
- StrongBuy: 3
- Buy: 3
- Hold: 6
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the IDXX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 752.2 | 16.7% |
| Analysts Target Price | 752.2 | 16.7% |
| ValueRay Target Price | 693 | 7.5% |
IDXX Fundamental Data Overview February 07, 2026
P/E Trailing = 49.2795
P/E Forward = 45.045
P/S = 11.9642
P/B = 31.9797
P/EG = 3.8208
Revenue TTM = 4.30b USD
EBIT TTM = 1.05b USD
EBITDA TTM = 1.47b USD
Long Term Debt = 374.8m USD (from longTermDebt, two quarters ago)
Short Term Debt = 473.0m USD (from shortTermDebt, last quarter)
Debt = 847.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 667.8m USD (from netDebt column, last quarter)
Enterprise Value = 52.16b USD (51.49b + Debt 847.8m - CCE 180.1m)
Interest Coverage Ratio = 27.36 (Ebit TTM 1.05b / Interest Expense TTM 38.3m)
EV/FCF = 49.34x (Enterprise Value 52.16b / FCF TTM 1.06b)
FCF Yield = 2.03% (FCF TTM 1.06b / Enterprise Value 52.16b)
FCF Margin = 24.56% (FCF TTM 1.06b / Revenue TTM 4.30b)
Net Margin = 24.62% (Net Income TTM 1.06b / Revenue TTM 4.30b)
Gross Margin = 61.80% ((Revenue TTM 4.30b - Cost of Revenue TTM 1.64b) / Revenue TTM)
Gross Margin QoQ = 60.35% (prev 61.83%)
Tobins Q-Ratio = 15.57 (Enterprise Value 52.16b / Total Assets 3.35b)
Interest Expense / Debt = 1.02% (Interest Expense 8.62m / Debt 847.8m)
Taxrate = 19.15% (58.8m / 307.0m)
NOPAT = 846.4m (EBIT 1.05b * (1 - 19.15%))
Current Ratio = 1.23 (Total Current Assets 1.41b / Total Current Liabilities 1.15b)
Debt / Equity = 0.53 (Debt 847.8m / totalStockholderEquity, last quarter 1.61b)
Debt / EBITDA = 0.45 (Net Debt 667.8m / EBITDA 1.47b)
Debt / FCF = 0.63 (Net Debt 667.8m / FCF TTM 1.06b)
Total Stockholder Equity = 1.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 31.89% (Net Income 1.06b / Total Assets 3.35b)
RoE = 69.78% (Net Income TTM 1.06b / Total Stockholder Equity 1.52b)
RoCE = 55.30% (EBIT 1.05b / Capital Employed (Equity 1.52b + L.T.Debt 374.8m))
RoIC = 33.89% (NOPAT 846.4m / Invested Capital 2.50b)
WACC = 9.42% (E(51.49b)/V(52.34b) * Re(9.56%) + D(847.8m)/V(52.34b) * Rd(1.02%) * (1-Tc(0.19)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.96%
[DCF Debug] Terminal Value 76.79% ; FCFF base≈953.5m ; Y1≈1.18b ; Y5≈2.00b
Fair Price DCF = 320.4 (EV 26.26b - Net Debt 667.8m = Equity 25.59b / Shares 79.9m; r=9.42% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 78.43 | EPS CAGR: 8.48% | SUE: 1.83 | # QB: 12
Revenue Correlation: 93.72 | Revenue CAGR: 7.33% | SUE: 1.07 | # QB: 3
EPS next Quarter (2026-03-31): EPS=3.43 | Chg30d=+0.021 | Revisions Net=-1 | Analysts=11
EPS current Year (2026-12-31): EPS=14.51 | Chg30d=+0.091 | Revisions Net=+0 | Growth EPS=+10.9% | Growth Revenue=+8.6%
EPS next Year (2027-12-31): EPS=16.35 | Chg30d=-0.056 | Revisions Net=-3 | Growth EPS=+12.7% | Growth Revenue=+8.7%
P/E Forward = 45.045
P/S = 11.9642
P/B = 31.9797
P/EG = 3.8208
Revenue TTM = 4.30b USD
EBIT TTM = 1.05b USD
EBITDA TTM = 1.47b USD
Long Term Debt = 374.8m USD (from longTermDebt, two quarters ago)
Short Term Debt = 473.0m USD (from shortTermDebt, last quarter)
Debt = 847.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 667.8m USD (from netDebt column, last quarter)
Enterprise Value = 52.16b USD (51.49b + Debt 847.8m - CCE 180.1m)
Interest Coverage Ratio = 27.36 (Ebit TTM 1.05b / Interest Expense TTM 38.3m)
EV/FCF = 49.34x (Enterprise Value 52.16b / FCF TTM 1.06b)
FCF Yield = 2.03% (FCF TTM 1.06b / Enterprise Value 52.16b)
FCF Margin = 24.56% (FCF TTM 1.06b / Revenue TTM 4.30b)
Net Margin = 24.62% (Net Income TTM 1.06b / Revenue TTM 4.30b)
Gross Margin = 61.80% ((Revenue TTM 4.30b - Cost of Revenue TTM 1.64b) / Revenue TTM)
Gross Margin QoQ = 60.35% (prev 61.83%)
Tobins Q-Ratio = 15.57 (Enterprise Value 52.16b / Total Assets 3.35b)
Interest Expense / Debt = 1.02% (Interest Expense 8.62m / Debt 847.8m)
Taxrate = 19.15% (58.8m / 307.0m)
NOPAT = 846.4m (EBIT 1.05b * (1 - 19.15%))
Current Ratio = 1.23 (Total Current Assets 1.41b / Total Current Liabilities 1.15b)
Debt / Equity = 0.53 (Debt 847.8m / totalStockholderEquity, last quarter 1.61b)
Debt / EBITDA = 0.45 (Net Debt 667.8m / EBITDA 1.47b)
Debt / FCF = 0.63 (Net Debt 667.8m / FCF TTM 1.06b)
Total Stockholder Equity = 1.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 31.89% (Net Income 1.06b / Total Assets 3.35b)
RoE = 69.78% (Net Income TTM 1.06b / Total Stockholder Equity 1.52b)
RoCE = 55.30% (EBIT 1.05b / Capital Employed (Equity 1.52b + L.T.Debt 374.8m))
RoIC = 33.89% (NOPAT 846.4m / Invested Capital 2.50b)
WACC = 9.42% (E(51.49b)/V(52.34b) * Re(9.56%) + D(847.8m)/V(52.34b) * Rd(1.02%) * (1-Tc(0.19)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.96%
[DCF Debug] Terminal Value 76.79% ; FCFF base≈953.5m ; Y1≈1.18b ; Y5≈2.00b
Fair Price DCF = 320.4 (EV 26.26b - Net Debt 667.8m = Equity 25.59b / Shares 79.9m; r=9.42% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 78.43 | EPS CAGR: 8.48% | SUE: 1.83 | # QB: 12
Revenue Correlation: 93.72 | Revenue CAGR: 7.33% | SUE: 1.07 | # QB: 3
EPS next Quarter (2026-03-31): EPS=3.43 | Chg30d=+0.021 | Revisions Net=-1 | Analysts=11
EPS current Year (2026-12-31): EPS=14.51 | Chg30d=+0.091 | Revisions Net=+0 | Growth EPS=+10.9% | Growth Revenue=+8.6%
EPS next Year (2027-12-31): EPS=16.35 | Chg30d=-0.056 | Revisions Net=-3 | Growth EPS=+12.7% | Growth Revenue=+8.7%